US 12,031,131 B2
RNA-editing oligonucleotides and uses thereof
Andrew W. Fraley, Arlington, MA (US); Steven Robinette, Fremont, NH (US); Nessan Bermingham, Boston, MA (US); and Mallikarjuna Reddy Putta, Lexington, MA (US)
Assigned to KORRO BIO, INC., Cambridge, MA (US)
Filed by Korro Bio, Inc., Cambridge, MA (US)
Filed on May 3, 2023, as Appl. No. 18/311,416.
Application 18/311,416 is a continuation of application No. 17/817,874, filed on Aug. 5, 2022.
Application 17/817,874 is a continuation of application No. 16/749,601, filed on Jan. 22, 2020, granted, now 11,453,878, issued on Sep. 27, 2022.
Claims priority of provisional application 62/900,017, filed on Sep. 13, 2019.
Claims priority of provisional application 62/822,586, filed on Mar. 22, 2019.
Claims priority of provisional application 62/795,348, filed on Jan. 22, 2019.
Prior Publication US 2023/0340464 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/11 (2006.01)
CPC C12N 15/11 (2013.01) [C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/351 (2013.01)] 27 Claims
 
1. An oligonucleotide comprising the structure:
[Am]-X1—X2—X3—[Bn]
wherein each of A and B is a nucleotide, wherein at least 20% of the nucleotides of [Am] and [Bn] combined are 2′-O-methyl-nucleotides;
m and n are each, independently, an integer from 1 to 50;
X1, X2, and X3 are each, independently, a nucleotide, wherein X2 has the structure of Formula II:

OG Complex Work Unit Chemistry
wherein N1 is a nucleobase;
R8 is hydrogen; and
R9 is hydrogen.